Agency Information Collection Activities: Submission for OMB Review; Comment Request, 70502-70503 [2021-26816]

Download as PDF 70502 Federal Register / Vol. 86, No. 235 / Friday, December 10, 2021 / Notices ++ The Joint Commission’s capacity to adequately fund required surveys. ++ The Joint Commission’s policies with respect to whether surveys are announced or unannounced, to assure that surveys are unannounced. ++ The Joint Commission’s policies and procedures to avoid conflicts of interest, including the appearance of conflicts of interest, involving individuals who conduct surveys or participate in accreditation decisions. ++ The Joint Commission’s agreement to provide CMS with a copy of the most current accreditation survey together with any other information related to the survey as we may require (including corrective action plans). IV. Collection of Information Requirements This document does not impose information collection requirements, that is, reporting, recordkeeping or third-party disclosure requirements. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). V. Response to Comments Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this preamble, and, when we proceed with a subsequent document, we will respond to the comments in the preamble to that document. The Administrator of the Centers for Medicare & Medicaid Services (CMS), Chiquita Brooks-LaSure, having reviewed and approved this document, authorizes Lynette Wilson, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the Federal Register. jspears on DSK121TN23PROD with NOTICES1 Dated: December 7, 2021. Lynette Wilson, Federal Register Liaison, Centers for Medicare & Medicaid Services. [FR Doc. 2021–26822 Filed 12–9–21; 8:45 am] BILLING CODE 4120–01–P VerDate Sep<11>2014 17:03 Dec 09, 2021 Jkt 256001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier CMS–R–153, CMS– 10561 and CMS–10657] Agency Information Collection Activities: Submission for OMB Review; Comment Request Centers for Medicare & Medicaid Services, Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. SUMMARY: Comments on the collection(s) of information must be received by the OMB desk officer by January 10, 2022. ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following: 1. Access CMS’ website address at website address at: https:// www.cms.gov/Regulations-andGuidance/Legislation/Paperwork ReductionActof1995/PRA-Listing.html. DATES: PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786–4669. Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term ‘‘collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment: 1. Type of Information Collection Request: Revision of a currently approved collection; Title of Information Collection: Medicaid Drug Use Review (DUR) Program; Use: States must provide for a review of drug therapy before each prescription is filled or delivered to a Medicaid patient. This review includes screening for potential drug therapy problems due to therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse/misuse. Pharmacists must make a reasonable effort to obtain, record, and maintain Medicaid patient profiles. These profiles must reflect at least the patient’s name, address, telephone number, date of birth/age, gender, history, e.g., allergies, drug reactions, list of medications, and pharmacist’s comments relevant to the individual’s drug therapy. The States must conduct RetroDUR which provides for the ongoing periodic examination of claims data and other records in order to identify patterns of fraud, abuse, inappropriate or medically unnecessary care. Patterns or trends of drug therapy problems are identified and reviewed to determine the need for intervention activity with pharmacists and/or physicians. States may conduct interventions via telephone, correspondence, or face-to-face contact. Annual reports are submitted to CMS for the purposes of monitoring compliance and evaluating the progress of States’ DUR programs. The SUPPLEMENTARY INFORMATION: E:\FR\FM\10DEN1.SGM 10DEN1 jspears on DSK121TN23PROD with NOTICES1 Federal Register / Vol. 86, No. 235 / Friday, December 10, 2021 / Notices information submitted by States is reviewed and results are compiled by CMS in a format intended to provide information, comparisons, and trends related to States’ experiences with DUR. States benefit from the information and may enhance their programs each year based on State reported innovative practices that are compiled by CMS from the DUR annual reports. In this 2021 collection of information request, we revised certain FFS, MCO, and Abbreviated MCO survey questions. While a few questions were added to the surveys to address GAO (U.S. Government Accountability Office) recommendations, other aspects of the survey changes include grammar and formatting edits. Overall, we are not revising our currently approved burden estimates. Form Number: CMS–R–153 (OMB control number: 0938–0659); Frequency: Yearly, quarterly, and occasionally; Affected Public: State, Local, or Tribal Governments; Number of Respondents: 51; Total Annual Responses: 663; Total Annual Hours: 41,004. (For policy questions regarding this collection contact Mike Forman at 410–786–2666.) 2. Type of Information Collection Request: Extension of a currently approved collection; Title of Information Collection: Supporting Statement for Essential Community Provider Data Collection to Support QHP Certification for PYs 2022–2024; Use: Standards for Essential Community Provider (ECP) requirements are codified at 45 CFR 156.235. Issuers must contract with a certain percentage, as determined by HHS, of the available ECPs in the plan’s service area. For plan years 2022–2024, Health and Human Services (HHS) will continue to solicit qualified ECPs to complete and submit the HHS ECP provider petition in order to be added to the HHS ECP list, or update required data fields to remain on the list, resulting in a more robust and accurate listing of the universe of available ECPs from which issuers select to satisfy the ECP standard. HHS will continue to collect such data directly from providers through the online ECP provider petition. Form Number: CMS– 10561; Frequency: Annually; Affected Public: Private sector, Business or other for-profits, and Not-for-profit Institutions; Number of Respondents: 12,408; Number of Responses: 12,408; Total Annual Hours: 3,140. (For questions regarding this collection, contact Deborah Hunter at 443–386– 3651). 3. Type of Information Collection Request: Revision of a currently approved collection; Title of Information Collection: The State VerDate Sep<11>2014 17:03 Dec 09, 2021 Jkt 256001 Flexibility to Stabilize the Market Cycle I and II Grant Program Reporting; Use: Section 1003 of the Affordable Care Act (ACA) adds a new section 2794 to the Public Health Service Act (PHS Act) entitled, ‘‘Ensuring That Consumers Get Value for Their Dollars.’’ Specifically, section 2794(a) requires the Secretary of the Department of Health and Human Services (the Secretary) (HHS), in conjunction with the States, to establish a process for the annual review of health insurance premiums to protect consumers from unreasonable rate increases. Section 2794(c) directs the Secretary to carry out a program to award grants to States. Section 2794(c)(2)(B) specifies that any appropriated Rate Review Grant funds that are not fully obligated by the end of FY 2014 shall remain available to the Secretary for grants to States for planning and implementing the insurance market reforms and consumer protections under Part A of title XXVII of the (PHS Act. States that are awarded funds under this funding opportunity are required to provide CMS with four quarterly reports and one annual report (except for the last year of the grant) until the end of the grant period detailing the state’s progression towards planning and/or implementing the preselected market reforms under Part A of Title XXVII of the PHS Act. A final report is due at the end of the grant period. Form Number: CMS–10657 (OMB control number: 0938–1366); Frequency: Annually and Quarterly; Affected Public: State, Local or Tribal Governments; Number of Respondents: 34; Total Annual Responses: 170; Total Annual Hours: 2,312. (For policy questions regarding this collection contact Jim Taing at James.Taing@ cms.hhs.gov.) 70503 The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ‘‘Development of Anti-Infective Drug Products for the Pediatric Population.’’ The purpose of this guidance is to provide general recommendations on the development of anti-infective drug products for pediatric patients. The guidance addresses enrollment strategies, extrapolation of efficacy, safety database, and other considerations to help facilitate pediatric anti-infective drug product development. This guidance finalizes the draft guidance of the same title issued on June 30, 2020. DATES: The announcement of the guidance is published in the Federal Register on December 10, 2021. ADDRESSES: You may submit either electronic or written comments on Agency guidances at any time as follows: SUMMARY: Electronic Submissions DEPARTMENT OF HEALTH AND HUMAN SERVICES Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Food and Drug Administration Written/Paper Submissions [Docket No. FDA–2020–D–1518] Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Dated: December 7, 2021. William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. [FR Doc. 2021–26816 Filed 12–9–21; 8:45 am] BILLING CODE 4120–01–P Development of Anti-Infective Drug Products for the Pediatric Population; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: PO 00000 Notice of availability. Frm 00074 Fmt 4703 Sfmt 4703 E:\FR\FM\10DEN1.SGM 10DEN1

Agencies

[Federal Register Volume 86, Number 235 (Friday, December 10, 2021)]
[Notices]
[Pages 70502-70503]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26816]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier CMS-R-153, CMS-10561 and CMS-10657]


Agency Information Collection Activities: Submission for OMB 
Review; Comment Request

AGENCY: Centers for Medicare & Medicaid Services, Health and Human 
Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is 
announcing an opportunity for the public to comment on CMS' intention 
to collect information from the public. Under the Paperwork Reduction 
Act of 1995 (PRA), federal agencies are required to publish notice in 
the Federal Register concerning each proposed collection of 
information, including each proposed extension or reinstatement of an 
existing collection of information, and to allow a second opportunity 
for public comment on the notice. Interested persons are invited to 
send comments regarding the burden estimate or any other aspect of this 
collection of information, including the necessity and utility of the 
proposed information collection for the proper performance of the 
agency's functions, the accuracy of the estimated burden, ways to 
enhance the quality, utility, and clarity of the information to be 
collected, and the use of automated collection techniques or other 
forms of information technology to minimize the information collection 
burden.

DATES: Comments on the collection(s) of information must be received by 
the OMB desk officer by January 10, 2022.

ADDRESSES: Written comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
    To obtain copies of a supporting statement and any related forms 
for the proposed collection(s) summarized in this notice, you may make 
your request using one of following:
    1. Access CMS' website address at website address at: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html.

FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786-4669.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. The term ``collection of 
information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and 
includes agency requests or requirements that members of the public 
submit reports, keep records, or provide information to a third party. 
Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires 
federal agencies to publish a 30-day notice in the Federal Register 
concerning each proposed collection of information, including each 
proposed extension or reinstatement of an existing collection of 
information, before submitting the collection to OMB for approval. To 
comply with this requirement, CMS is publishing this notice that 
summarizes the following proposed collection(s) of information for 
public comment:
    1. Type of Information Collection Request: Revision of a currently 
approved collection; Title of Information Collection: Medicaid Drug Use 
Review (DUR) Program; Use: States must provide for a review of drug 
therapy before each prescription is filled or delivered to a Medicaid 
patient. This review includes screening for potential drug therapy 
problems due to therapeutic duplication, drug-disease 
contraindications, drug-drug interactions, incorrect drug dosage or 
duration of drug treatment, drug-allergy interactions, and clinical 
abuse/misuse. Pharmacists must make a reasonable effort to obtain, 
record, and maintain Medicaid patient profiles. These profiles must 
reflect at least the patient's name, address, telephone number, date of 
birth/age, gender, history, e.g., allergies, drug reactions, list of 
medications, and pharmacist's comments relevant to the individual's 
drug therapy.
    The States must conduct RetroDUR which provides for the ongoing 
periodic examination of claims data and other records in order to 
identify patterns of fraud, abuse, inappropriate or medically 
unnecessary care. Patterns or trends of drug therapy problems are 
identified and reviewed to determine the need for intervention activity 
with pharmacists and/or physicians. States may conduct interventions 
via telephone, correspondence, or face-to-face contact.
    Annual reports are submitted to CMS for the purposes of monitoring 
compliance and evaluating the progress of States' DUR programs. The

[[Page 70503]]

information submitted by States is reviewed and results are compiled by 
CMS in a format intended to provide information, comparisons, and 
trends related to States' experiences with DUR. States benefit from the 
information and may enhance their programs each year based on State 
reported innovative practices that are compiled by CMS from the DUR 
annual reports.
    In this 2021 collection of information request, we revised certain 
FFS, MCO, and Abbreviated MCO survey questions. While a few questions 
were added to the surveys to address GAO (U.S. Government 
Accountability Office) recommendations, other aspects of the survey 
changes include grammar and formatting edits. Overall, we are not 
revising our currently approved burden estimates.
    Form Number: CMS-R-153 (OMB control number: 0938-0659); Frequency: 
Yearly, quarterly, and occasionally; Affected Public: State, Local, or 
Tribal Governments; Number of Respondents: 51; Total Annual Responses: 
663; Total Annual Hours: 41,004. (For policy questions regarding this 
collection contact Mike Forman at 410-786-2666.)
    2. Type of Information Collection Request: Extension of a currently 
approved collection; Title of Information Collection: Supporting 
Statement for Essential Community Provider Data Collection to Support 
QHP Certification for PYs 2022-2024; Use: Standards for Essential 
Community Provider (ECP) requirements are codified at 45 CFR 156.235. 
Issuers must contract with a certain percentage, as determined by HHS, 
of the available ECPs in the plan's service area. For plan years 2022-
2024, Health and Human Services (HHS) will continue to solicit 
qualified ECPs to complete and submit the HHS ECP provider petition in 
order to be added to the HHS ECP list, or update required data fields 
to remain on the list, resulting in a more robust and accurate listing 
of the universe of available ECPs from which issuers select to satisfy 
the ECP standard. HHS will continue to collect such data directly from 
providers through the online ECP provider petition. Form Number: CMS-
10561; Frequency: Annually; Affected Public: Private sector, Business 
or other for-profits, and Not-for-profit Institutions; Number of 
Respondents: 12,408; Number of Responses: 12,408; Total Annual Hours: 
3,140. (For questions regarding this collection, contact Deborah Hunter 
at 443-386-3651).
    3. Type of Information Collection Request: Revision of a currently 
approved collection; Title of Information Collection: The State 
Flexibility to Stabilize the Market Cycle I and II Grant Program 
Reporting; Use: Section 1003 of the Affordable Care Act (ACA) adds a 
new section 2794 to the Public Health Service Act (PHS Act) entitled, 
``Ensuring That Consumers Get Value for Their Dollars.'' Specifically, 
section 2794(a) requires the Secretary of the Department of Health and 
Human Services (the Secretary) (HHS), in conjunction with the States, 
to establish a process for the annual review of health insurance 
premiums to protect consumers from unreasonable rate increases. Section 
2794(c) directs the Secretary to carry out a program to award grants to 
States. Section 2794(c)(2)(B) specifies that any appropriated Rate 
Review Grant funds that are not fully obligated by the end of FY 2014 
shall remain available to the Secretary for grants to States for 
planning and implementing the insurance market reforms and consumer 
protections under Part A of title XXVII of the (PHS Act. States that 
are awarded funds under this funding opportunity are required to 
provide CMS with four quarterly reports and one annual report (except 
for the last year of the grant) until the end of the grant period 
detailing the state's progression towards planning and/or implementing 
the pre-selected market reforms under Part A of Title XXVII of the PHS 
Act. A final report is due at the end of the grant period. Form Number: 
CMS-10657 (OMB control number: 0938-1366); Frequency: Annually and 
Quarterly; Affected Public: State, Local or Tribal Governments; Number 
of Respondents: 34; Total Annual Responses: 170; Total Annual Hours: 
2,312. (For policy questions regarding this collection contact Jim 
Taing at [email protected].)

    Dated: December 7, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and 
Regulatory Affairs.
[FR Doc. 2021-26816 Filed 12-9-21; 8:45 am]
BILLING CODE 4120-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.